Considerations over a Case of Suspected Therapeutic Failure in Pediatric Patients after Switching Valproate Manufacturers
Introduction: Product switching followed by suspected adverse events are common and unsettling for antiepileptic drugs. The objective of this case study was to describe the investigation performed after report of suspected therapeutic failure in pediatric patients following a switch to a different...
Main Authors: | Jaqueline Kalleian Eserian, Jair Ribeiro Chagas, José Carlos Fernandes Galduróz |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Minnesota Libraries Publishing
2020-08-01
|
Series: | INNOVATIONS in Pharmacy |
Subjects: | |
Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/3315 |
Similar Items
-
Suspected hepatotoxicity and thrombocytopenia: Sodium valproate and carbamazepine
by: Siddhi Umarje, et al.
Published: (2018-01-01) -
Comparison of the Therapeutic Effects of Sodium Valproate and Levetiracetam on Pediatric Epilepsy and the Effects of Nerve Growth Factor and γ-Aminobutyric Acid
by: Min CHEN, et al.
Published: (2021-02-01) -
The menacing side of valproate: A case series of valproate-induced hyperammonemia
by: Deeksha Elwadhi, et al.
Published: (2017-01-01) -
Platelet Function and Valproate
by: J Gordon Millichap
Published: (1999-03-01) -
Topiramate-Induced Valproate Toxicity
by: J Gordon Millichap
Published: (2002-04-01)